Skip to main content
SpringerLink
Log in

Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

In low volume testicular cancer, (clinical stage A/B1) retroperitoneal lymph node dissection has maintained its therapeutic benefit while minimizing morbidity with the reduction of the surgical template from a full bilateral dissection to a unilateral nerve-sparring surgery. The optimal treatment for low stage disease is largely patient driven with surgery and surveillance considered the primary treatment modalities. In the post chemotherapy population, patients with complete radiographic resolution of retroperitoneal disease are observed at Indiana University as the relapse rate in this population is ~5%. Residual masses after chemotherapy should be resected. A modified post chemotherapy dissection is adequate in low volume disease restricted to the primary landing zone of the affected testicle. In chemo-refractory disease, aggressive surgery provides a 5 year survival of 31% for patients with active cancer. Excluding chemo-naïve patients, late relapse disease is managed surgically with 50% being cured of disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Richie JP, Kantoff PW (1991) Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol 9:1393

    PubMed  CAS  Google Scholar 

  2. Rabbani F, Sheinfeld J, Farivar-Mohseni H et al (2001) Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 19:2020

    PubMed  CAS  Google Scholar 

  3. Williams SD, Stablein DM, Einhorn LH et al (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317:1433

    Article  PubMed  CAS  Google Scholar 

  4. Hartlapp JH, Weissbach L, Bussar-Maatz R (1987) Adjuvant chemotherapy in nonseminomatous testicular tumour stage II. Int J Androl 10:277

    Article  PubMed  CAS  Google Scholar 

  5. Donohue JP, Thornhill JA, Foster RS et al (1993) Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 149:237

    PubMed  CAS  Google Scholar 

  6. Donohue JP, Thornhill JA, Foster RS et al (1995) Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965–1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer 31A:1599

    Article  PubMed  CAS  Google Scholar 

  7. Sweeney CJ, Hermans BP, Heilman DK et al (2000) Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma–predominant testis cancer. J Clin Oncol 18:358

    PubMed  CAS  Google Scholar 

  8. Beck SD, Foster RS, Bihrle R et al (2005) Does the histology of nodal metastasis predict systemic relapse after retroperitoneal lymph node dissection in pathological stage B1 germ cell tumors? J Urol 174:1287

    Article  PubMed  Google Scholar 

  9. Beck SD, Foster RS, Bihrle R et al (2005) Impact of the number of positive lymph nodes on disease-free survival in patients with pathological stage B1 nonseminomatous germ cell tumor. J Urol 174:143

    Article  PubMed  Google Scholar 

  10. Behnia M, Foster R, Einhorn LH et al (2000) Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. Eur J Cancer 36:472

    Article  PubMed  CAS  Google Scholar 

  11. Motzer RJ, Sheinfeld J, Mazumdar M et al (1995) Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol 13:2700

    PubMed  CAS  Google Scholar 

  12. Foster RS, McNulty A, Rubin LR et al (1994) Fertility considerations in nerve-sparing retroperitoneal lymph-node dissection. World J Urol 12:136

    PubMed  CAS  Google Scholar 

  13. Heidenreich A, Albers P, Hartmann M et al (2003) Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 169:1710

    Article  PubMed  Google Scholar 

  14. Jewett MA (1990) Nerve-sparing technique for retroperitoneal lymphadenectomy in testis cancer. Urol Clin North Am 17:449

    PubMed  CAS  Google Scholar 

  15. Baniel J, Foster RS, Rowland RG et al (1994) Complications of primary retroperitoneal lymph node dissection. J Urol 152:424

    PubMed  CAS  Google Scholar 

  16. Amato RJ, Ro JY, Ayala AG et al (2004) Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology 63:144

    Article  PubMed  Google Scholar 

  17. Bohlen D, Borner M, Sonntag RW et al (1999) Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 161:1148

    Article  PubMed  CAS  Google Scholar 

  18. Chevreau C, Mazerolles C, Soulie M et al (2004) Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 46:209

    Article  PubMed  CAS  Google Scholar 

  19. Oliver RT, Ong J, Shamash J et al (2004) Long-term follow-up of Anglian germ cell cancer group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 63:556

    Article  PubMed  CAS  Google Scholar 

  20. Pont J, Albrecht W, Postner G et al (1996) Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 14:441

    PubMed  CAS  Google Scholar 

  21. Debono DJ, Heilman DK, Einhorn LH et al (1997) Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 15:1455

    PubMed  CAS  Google Scholar 

  22. Donohue JP, Foster RS (1994) Management of retroperitoneal recurrences: Seminoma and Nonseminoma. In: Urologic clinics of north america, vol. 21, pp 761–772

  23. Vergouwe Y, Steyerberg EW, de Wit R et al (2003) External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. Br J Cancer 88:843

    Article  PubMed  CAS  Google Scholar 

  24. Loehrer PJ Sr, Hui S, Clark S et al (1986) Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation. J Urol 135:1183

    PubMed  Google Scholar 

  25. Tait D, Peckham MJ, Hendry WF et al (1984) Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 50:601

    PubMed  CAS  Google Scholar 

  26. Stenning SP, Parkinson MC, Fisher C et al (1998) Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical research council testicular tumour working party. Cancer 83:1409

    Article  PubMed  CAS  Google Scholar 

  27. Fizazi K, Tjulandin S, Salvioni R et al (2001) Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy–results from an international study group. J Clin Oncol 19:2647

    PubMed  CAS  Google Scholar 

  28. Einhorn LH, Williams SD, Mandelbaum I et al (1981) Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 48:904

    Article  PubMed  CAS  Google Scholar 

  29. Donohue JP, Zachary JM, Maynard BR (1982) Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 128:315

    PubMed  CAS  Google Scholar 

  30. Foster RS, Donohue JP, Bihrle R (1991) Stage A nonseminomatous testis carcinoma: rationale and results of nerve-sparing retroperitoneal lymphadenectomy. Urol Int 46:294

    Article  PubMed  CAS  Google Scholar 

  31. Wood DP Jr, Herr HW, Heller G et al (1992) Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 148:1812

    PubMed  Google Scholar 

  32. Rabbani F, Goldenberg SL, Gleave ME et al (1998) Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of residual masses sufficient? Br J Urol 81:295

    PubMed  CAS  Google Scholar 

  33. Oldenburg J, Alfsen GC, Lien HH et al (2003) Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 21:3310

    Article  PubMed  Google Scholar 

  34. Beck SDW, Foster RS, Bihrle R et al (2005) Is full bilateral retroperitoneal lymph node dissection always necessary for post chemotherapy resdual tumor? AUA, San Antonia Texas, Abstract

  35. Donohue JP, Leviovitch I, Foster RS et al (1998) Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol 16:65

    PubMed  CAS  Google Scholar 

  36. McKiernan JM, Motzer RJ, Bajorin DF et al (2003) Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology 62:732

    Article  PubMed  Google Scholar 

  37. Beck SD, Foster RS, Bihrle R et al (2005) Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 23:6149

    Article  PubMed  Google Scholar 

  38. George DW, Foster RS, Hromas RA et al (2003) Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol 21:113

    Article  PubMed  Google Scholar 

  39. Dieckmann KP, Albers P, Classen J et al (2005) Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol 173:824

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Indiana Cancer Pavilion, Indiana University Medical School, 535 N. Barnhill Drive, Suite 420, Indianapolis, IN, 46202, USA

    Stephen D. W. Beck & Richard S. Foster

Authors
  1. Stephen D. W. Beck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard S. Foster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen D. W. Beck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beck, S.D.W., Foster, R.S. Long-term outcome of retroperitoneal lymph node dissection in the management of testis cancer. World J Urol 24, 267–272 (2006). https://doi.org/10.1007/s00345-006-0060-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-006-0060-8

Keywords

Search

Navigation